Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc. (XENE): 10 pipeline candidates · 8 upcoming catalysts · ~36 mo cash runway · 13 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
36.1 months
D/E 0.04 · 0% dilution
Lead: Phase 3
10 candidates
8 upcoming, next in ~105d
0 buys · 19 sells (180d)
A transparent, data-derived signal for Xenon Pharmaceuticals Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$5.0B
Cash
$545.9M
Quarterly Burn
$88.9M
Runway
36.1 mo
Revenue
$0
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (10 candidates)
| Drug | Phase |
|---|---|
| azetukalner | Phase 3 |
| kv7 development candidates | Preclinical |
| nav1.1 lead candidate | Preclinical |
| nav1.1 program | Preclinical |
| nav1.7 lead candidate | Preclinical |
| nbi-921352 | Phase 2 |
| nbi-921355 | Phase 1 |
| xen1101 | Phase 3 |
| xen1120 | Phase 3 |
| xen1701 | Phase 3 |
Upcoming Catalysts (8)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
291
Total value held
$5.52B
| Holder | Shares | Value |
|---|---|---|
| fmr llc | 10,818,491 | $629.1M |
| janus henderson group plc | 8,351,964 | $485.7M |
| blackrock, inc. | 5,640,118 | $328.0M |
| wellington management group llp | 4,829,641 | $280.8M |
| driehaus capital management llc | 4,491,653 | $261.2M |
| polar capital holdings plc | 4,405,312 | $256.2M |
| citadel advisors llc | 2,886,390 | $167.8M |
| state street corp | 1,720,533 | $100.0M |
| susquehanna international group, llp | 1,695,037 | $98.6M |
| affinity asset advisors, llc | 1,675,000 | $97.4M |
Showing top 10 of 291 institutional holders of Xenon Pharmaceuticals Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Xenon Pharmaceuticals Inc.'s pipeline?
Xenon Pharmaceuticals Inc. (XENE) has 10 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Xenon Pharmaceuticals Inc.'s lead drug candidate?
Xenon Pharmaceuticals Inc.'s most advanced tracked candidate is azetukalner (Phase 3) for Major Depressive Disorder; Bipolar Depression; Bipolar Disorder.
What is Xenon Pharmaceuticals Inc.'s next catalyst?
Xenon Pharmaceuticals Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Evaluate Azetukalner i" — expected October 1, 2026.
What is Xenon Pharmaceuticals Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Xenon Pharmaceuticals Inc. has approximately 36.1 months of cash runway.
What is Xenon Pharmaceuticals Inc.'s market capitalization?
Xenon Pharmaceuticals Inc.'s market capitalization is approximately $5.0B.
Get the full picture on Xenon Pharmaceuticals Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.